Single Agent Adjuncts Flashcards
ALPHAGAN P .1%
Indication
Contraindication
Admin
AE
DDI
max IOP reduction
-reduction of IOP in OAG or OHT
-neonates and infants, hypersensitivity to brimonidine or tartrate or any components
-TID, 8 hours apart
-allergic conjunctivitis, conjunctival hyperemia, eye pruritus
-antihypertensives, cardiac glycosides, CNS depressants, TCAs, MAO inhibitors
-2-6 mm Hg
BRIMONIDINE .15%
Indication
Contraindication
Admin
AE
DDI
max IOP reduction
-reduction of IOP in OAG or OHT
-neonates and infants, hypersensitivity to brimonidine or any components
-TID, about 8 hours apart
-allergic conjunctivitis, conjunctival hyperemia, eye pruritus
-anti hypertensives, cardiac glycosides, CNS depressant, TCAs, MAO inhibitors
-2-6 mm Hg
BRIMONIDINE .2%
Indication
Contra
Admin
AE
DDI
max IOP reduction
-reduction of IOP in OAG or OHT
-neonates and infants, hypersensitivity to brimonidine or any components
-TID, about 8 hours apart
-oral dryness
-anti hypertensives, cardiac glycosides, CNS depressant, TCAs, MAO inhibitors
-4-6 mm Hg
AZOPT
Indication
Contra
Admin
AE
DDI
max IOP reduction
-reduce IOP
-hypersensitivity to brinzolamide or any components
-TID
-blurred vision, dysgeusia
-oral CAIs, high dose salicylate
-4-5 mm Hg
TRUSOPT
indication
contra
admin
AE
DDI
max IOP
-reduction of elevated IOP
-hypersensitivity to dorzolamide hydrochloride or any components
-TID
-ocular irritation
-oral CAIs, high dose salicylate
-3-5 mm Hg
TIMOLOL
indication
contra
admin
AE
DDI
max IOP
-treatment of elevated IOP
-bronchial asthma, severe COPD, cardiac cardiac problems, hypersensitivity to timolol maleate or any of its components
-QD
-blurred vision or instillation
-oral b-blockers, digitalis, alcium antagonists, catecholamine-depleting drugs, quindidine, clonidine, injectable epinephrine
-6 mm Hg
ISOPTO CARPINE
indication
contra
admin
AE
DDI
max IOP
-reduction of elevated IOP, management of AACG, prevention of post op IOP increase from laser surgery, induction of miosis
-none
-up to QID
-accommodative change, blurred vision, ocular irritation/pain, visual impairment, headache/brow ache
-none
-3-7 mm Hg
ALPHAGAN P .1%
active ingredient
brimonidine tartrate .1% or .15%
ALPHAGAN P .1%
class
a-agonist
ALPHAGAN P .1%
proposed MOA
reduce aqueous production and increase uveoscleral outflow
ALPHAGAN P .1%
bottle size availability
5 mL in a 10 mL bottle
10 mL in a 10 mL bottle
15 mL in a 15 mL bottle
BRIMONIDINE .15%
active ingredient
brimonidine tartrate .15%
BRIMONIDINE .15%
class
a-agonist
BRIMONIDINE .15%
proposed MOA
reduce aqueous production and increase uveoscleral outflow
BRIMONIDINE .15%
bottle size availability
5 mL in a 5 mL bottle
10 mL in 11 mL bottle
15 mL in a 15 mL bottle
BRIMONIDINE .2%
active ingredient
brimonidine tartrate .2%
BRIMONIDINE .15%
class
a-agonist
BRIMONIDINE .15%
proposed MOA
reduced aqueous production and increase uveoscleral outflow
BRIMONIDINE .15%
bottle size
5 mL
10 mL
15 mL
AZOPT
active ingredient
brinzolamide 1%
AZOPT
class
CAI
AZOPT
proposed MOA
decrease aqueous production
AZOPT
bottle size
10 mL
15 mL
TRUSOPT
active ingredient
dorzolamide hydrochloride
AZOPT
class
CAI
AZOPT
proposed MOA
decrease aqueous production
AZOPT
bottle size
10 mL in 18 mL bottle
TIMOLO
active ingredient
timolo maleate .25% or .5%
TIMOLO
class
b-blocker
TIMOLO
proposed MOA
reduce aqueous formation, possibly also increase aqueous outflow
ISOPTO CARPINE
active ingredient
pilocarpine 1%, 2%, 4%
TIMOLO
bottle size
2.5 mL
5 mL
TIMOLO
class
cholinergic agonist
TIMOLO
proposed MOA
increase aqueous outflow
